Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2017

View Archived Issues

Novel mutation in IDS gene unveiled for Hunter syndrome

Chugai's RG-6107 named orphan drug in the U.S.

Autolus completes first dose cohort in APRIL study of AUTO2

Ultragenyx proposes to acquire Dimension Therapeutics

Emergent Biosolutions awarded funding to develop antidote spray for cyanide poisoning

Aeolus Pharmaceuticals' AEOL-10150 safe and well-tolerated in phase I study

TGFbeta-primed MDSCs as a novel adoptive cellular therapy to treat tumors

Phase II study of PBI-4050 in Alstrom syndrome shows beneficial clinical effects

NIH grant to support development of Cel-Sci's rheumatoid arthritis vaccine

Acceleron Pharma, Celgene amend sotatercept agreement

First-in-human phase I/II Lipo-MERIT trial of RNA cancer vaccine in malignant melanoma patients

Board recommends continuation of MGL-3196 studies

UCB discloses new plasmepsin V inhibitors for malaria treatment

Teva enters partnership with Nuvelution Pharma to develop Austedo for Tourette syndrome

Roche divulges BACE1 inhibitors

WDR5/KMT2A interaction inhibitors presented by OICR

Boehringer Ingelheim discovers SSAO inhibitors

Viera Bioscience presents Act Tregs for cardiovascular disorders

Topline data from phase III LEAP 1 study of lefamulin in community-acquired bacterial pneumonia

Q BioMed and Sphaera Pharma partner to develop QBM-001 analogue

Xermelo approved in Europe for carcinoid syndrome diarrhea

Incysus submits IND to FDA for allogeneic gamma-delta T-cell immunotherapy

Migalastat awarded FDA fast track designation for Fabry disease

Topline data reported from phase III IMPACT study of newly approved Trelegy Ellipta

Safety, efficacy and PK data presented for the novel inhaled bronchodilator AZD-8871

Arcus enters option and license agreement with Taiho in Japan and select Asian territories

Ophthotech gives update on Zimura clinical trials

Acer Therapeutics completes merger with Opexa Therapeutics

4D Molecular Therapeutics receives additional funding from Cystic Fibrosis Foundation Therapeutics

Synergy of ISA-101 vaccine and chemotherapy for the treatment of HPV-related diseases

European approval for Rydapt for two indications in rare, hard-to-treat cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...